血小板生成素受体激动剂增加免疫性血小板减少症患者脾脏调节性T细胞数量
该研究分析35例因原发性难治性免疫性血小板减少症(ITP)切除的脾脏,发现脾切除前使用血小板生成素受体激动剂(TPO-RA)与脾脏调节性T细胞、2型辅助性T细胞及组织细胞密度增加和红髓血窦减少相关,但手术结局与TPO-RA使用、其他脾切除前治疗及Treg密度无关。
要点
- 脾切除前TPO-RA使用与脾脏Treg、Th2细胞及组织细胞密度增加相关。
- TPO-RA使用与红髓血窦减少相关。
- 手术结局与TPO-RA使用、其他术前治疗及Treg密度均无关联。
核心结论
- TPO-RA影响ITP患者脾脏免疫微环境,但对脾切除结局无影响。
研究设计与样本
- 研究分析了35例因原发性难治性ITP而切除的脾脏。
主要发现
- 脾切除前TPO-RA给药与脾脏调节性T细胞增加相关。
- 脾切除前TPO-RA给药与2型辅助性T细胞增加相关。
- 脾切除前TPO-RA给药与组织细胞密度增加相关。
- 脾切除前TPO-RA给药与红髓血窦减少相关。
- 手术结局与TPO-RA给药、其他脾切除前治疗和/或Treg密度无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombopoietin receptor agonists (TPO-RA) are a valid therapy for immune thrombocytopenia (ITP), due to megakaryocyte stimulation and (poorly characterised) immune-modulatory effects. The spleen is pivotal in the pathogenesis of ITP, yet little is known on its immune microenvironment and on effects of TPO-RA on this organ. To address these topics, we analysed 35 spleens removed for primary refractory ITP. Pre-splenectomy TPO-RA administration correlated with increased splenic regulatory T cells (Tregs), type 2 T-helper cells and histiocyte density and with reduced red pulp sinusoids. Surgical outcome was not associated with TPO-RA administration, other pre-splenectomy therapies and/or Treg density. In conclusion, TPO-RA affect the splenic microenvironment, but this has no impact on splenectomy outcome.
引用
- Pizzi M, Vianello F, Binotto G, et al. Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia. Br J Haematol. 2022. PMID: 35701886. doi:10.1111/bjh.18309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。